Trials / Conditions / Peripheral T-Cell Lymphoma, Not Otherwise Specified

Peripheral T-Cell Lymphoma, Not Otherwise Specified

18 registered clinical trials studyying Peripheral T-Cell Lymphoma, Not Otherwise Specified — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas NCT07293403	City of Hope Medical Center	Phase 2
Not Yet Recruiting	Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cel NCT07278856	City of Hope Medical Center	Phase 1
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Not Yet Recruiting	Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patie NCT06724237	Eastern Cooperative Oncology Group	Phase 3
Recruiting	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Other NCT06561048	Corvus Pharmaceuticals, Inc.	Phase 3
Recruiting	Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463	Mayo Clinic	Phase 1
Recruiting	A Registry for People With T-cell Lymphoma NCT05978141	Memorial Sloan Kettering Cancer Center	—
Unknown	Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lympho NCT05821192	Ou Bai, MD/PHD	N/A
Suspended	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201	Alliance for Clinical Trials in Oncology	Phase 2
Terminated	Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymph NCT03590574	Autolus Limited	Phase 1 / Phase 2
Completed	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451	BeiGene	Phase 2
Active Not Recruiting	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym NCT03113500	City of Hope Medical Center	Phase 2
Completed	Risk Stratification of Nodal PTCL NCT03040206	Chonbuk National University Hospital	—
Completed	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715	Mayo Clinic	N/A
Completed	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphom NCT02561273	University of Nebraska	Phase 1 / Phase 2
Unknown	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL NCT02533700	Shandong Provincial Hospital	Phase 2
Active Not Recruiting	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409	Mayo Clinic	N/A
Completed	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma NCT00901147	Singapore General Hospital	Phase 2